Patent · US Expired

4-(4Methoxybenzyl)-n′-(5-nitro1,3-thiazol-2-yl)urea and its use in the treatment of conditions associated with glycogen-synthase kinase-3 (gsk3)

US7056939B2 · kind B2 · utility

1Cited by

0References

10Claims

0Family size

Assignee

ASTRAZENECA AB · SE

Inventors

Stefan Berg · Ekerö, SE
Sven Hellberg · Malung, SE

Key dates

Filing date	Jul 3, 2002
Grant date	Jun 6, 2006
Priority date	—
Expiry date	Dec 4, 2022

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a new compound of formula I as a free base or a pharmaceutically acceptable salt thereof, a process for the preparation, pharmaceutical formulations containing said therapeutically active compound and to the use of said compound in therapy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.